Business
Over £1 million of New Contract Wins
Over £1 million of New Contract Wins.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \n \n RNS Number : 9970N\n Cambridge Cognition Holdings PLC\n 27 May 2020\n \n \n \n \n \n \n \n Cambridge Cognition Holdings Plc\n \n \n (\"\n Cambridge Cognition\"\n \n or the \"Company\")\n \n \n \n \n \n Over £1 million of New Contract Wins\n \n \n \n \n \n Cambridge Cognition wins increasing numbers of virtual clinical trials during COVID-19\n \n \n \n \n \n Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that the Company has recently won several new contracts to support pharmaceutical clients in delivering virtual clinical trials, including two contracts collectively worth over £1 million - the majority of which is expected to be recognised this financial year. \n \n \n \n \n \n Traditionally, clinical trials build a comprehensive profile of the patient population from thorough, but infrequent, assessments in clinics. However, \n in efforts to curb COVID-19 transmission rates, the pharmaceutical industry has reduced site visits for their clinical trials and in some cases temporarily suspended patient recruitment. The broad expectation in the sector is that clinical trials are likely to resume in late Q2 or early Q3 2020. However, in search for an immediate solution and to reduce the chances of similar delays in the future, pharmaceutical companies are shifting from the traditional model of in-clinic assessments to, where possible, technology-driven solutions that support testing subjects remotely without the need for people to travel so frequently to clinical trial centres. \n \n \n \n \n \n Having delivered almost 50,000 assessments online, Cambridge Cognition has been supporting virtual clinical trials since the launch of its cloud-based platform in 2017. With pharmaceutical companies searching for options to continue trials outside of the clinic, the Company has seen increased interest in virtual or part-virtual assessments since COVID-19 driven lockdowns began. Cambridge Cognition has re-designed several ongoing studies for its customers so that they can continue virtually, with assessments now being completed in patients' homes rather than in clinics. With its robust record of collecting data remotely across 10 clinical trials globally, the Company has been awarded several n...